Holen Sie sich die Stockscreener-App
178.86
0.67%
-1.21
Handel nachbörslich:
178.86
Schlusskurs vom Vortag:
$180.07
Offen:
$178.46
24-Stunden-Volumen:
670.70K
Relative Volume:
0.70
Marktkapitalisierung:
$8.80B
Einnahmen:
$4.06B
Nettoeinkommen (Verlust:
$413.08M
KGV:
22.33
EPS:
8.01
Netto-Cashflow:
$560.48M
1W Leistung:
-8.41%
1M Leistung:
+0.86%
6M Leistung:
+50.99%
1J Leistung:
-1.16%
1-Tages-Spanne:
$173.89
$178.94
1-Wochen-Bereich:
$173.89
$193.47
52-Wochen-Spanne:
$91.86
$230.02
Charles River Laboratories International Inc Stock (CRL) Company Profile
Firmenname
Charles River Laboratories International Inc
Sektor
Branche
Telefon
781-222-6000
Adresse
251 BALLARDVALE ST, WILMINGTON, MA
Vergleichen Sie CRL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRL
Charles River Laboratories International Inc
|
178.86 | 8.86B | 4.06B | 413.08M | 560.48M | 8.01 |
|
TMO
Thermo Fisher Scientific Inc
|
564.88 | 213.17B | 43.74B | 6.59B | 6.11B | 17.30 |
|
DHR
Danaher Corp
|
214.06 | 152.13B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
722.94 | 50.36B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
144.69 | 41.49B | 6.79B | 1.22B | 1.09B | 4.2644 |
|
IQV
Iqvia Holdings Inc
|
213.88 | 36.86B | 15.90B | 1.28B | 2.21B | 7.2842 |
Charles River Laboratories International Inc Stock (CRL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-06 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2025-10-02 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2025-09-09 | Hochstufung | Jefferies | Hold → Buy |
| 2025-07-09 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-05-23 | Hochstufung | Redburn Atlantic | Neutral → Buy |
| 2025-05-14 | Hochstufung | TD Cowen | Hold → Buy |
| 2025-05-08 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2025-03-21 | Herabstufung | Goldman | Buy → Neutral |
| 2025-03-04 | Hochstufung | Citigroup | Sell → Neutral |
| 2025-03-03 | Hochstufung | Redburn Atlantic | Sell → Neutral |
| 2025-01-22 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2025-01-17 | Herabstufung | UBS | Buy → Neutral |
| 2024-11-18 | Herabstufung | CLSA | Hold → Underperform |
| 2024-11-07 | Hochstufung | CLSA | Underperform → Hold |
| 2024-10-23 | Eingeleitet | CLSA | Underperform |
| 2024-10-14 | Eingeleitet | Redburn Atlantic | Sell |
| 2024-10-07 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2024-10-02 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-10-01 | Herabstufung | Citigroup | Neutral → Sell |
| 2024-08-08 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-08-08 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-06-28 | Herabstufung | Argus | Buy → Hold |
| 2024-06-07 | Eingeleitet | Mizuho | Neutral |
| 2024-06-06 | Eingeleitet | Goldman | Buy |
| 2024-02-15 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-09-13 | Eingeleitet | TD Cowen | Market Perform |
| 2023-07-10 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-02-23 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-01-12 | Herabstufung | Jefferies | Buy → Hold |
| 2022-09-30 | Hochstufung | Jefferies | Hold → Buy |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-08-04 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-05-24 | Eingeleitet | Guggenheim | Neutral |
| 2022-04-25 | Herabstufung | Jefferies | Buy → Hold |
| 2022-04-07 | Eingeleitet | Stephens | Overweight |
| 2022-02-17 | Bestätigt | BofA Securities | Buy |
| 2022-02-17 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-02-17 | Bestätigt | Deutsche Bank | Buy |
| 2022-02-17 | Bestätigt | Morgan Stanley | Overweight |
| 2022-02-17 | Bestätigt | UBS | Buy |
| 2021-08-05 | Fortgesetzt | Credit Suisse | Neutral |
| 2020-12-16 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-09-10 | Hochstufung | Jefferies | Hold → Buy |
| 2020-07-01 | Hochstufung | BofA Securities | Neutral → Buy |
| 2020-05-13 | Hochstufung | UBS | Neutral → Buy |
| 2020-04-21 | Herabstufung | Jefferies | Buy → Hold |
| 2020-03-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-02 | Eingeleitet | Deutsche Bank | Buy |
| 2020-02-18 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2020-01-10 | Hochstufung | Goldman | Neutral → Buy |
| 2020-01-08 | Eingeleitet | Wells Fargo | Overweight |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2019-10-18 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-06-10 | Eingeleitet | SVB Leerink | Outperform |
| 2019-04-30 | Fortgesetzt | Evercore ISI | Outperform |
| 2018-12-14 | Eingeleitet | Deutsche Bank | Buy |
| 2018-10-09 | Eingeleitet | UBS | Neutral |
| 2018-08-23 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2018-07-17 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-06-15 | Hochstufung | KeyBanc Capital Mkts | Sector Weight → Overweight |
| 2018-02-14 | Hochstufung | SunTrust | Hold → Buy |
Alle ansehen
Charles River Laboratories International Inc Aktie (CRL) Neueste Nachrichten
Will Charles River Laboratories International Inc. stock maintain dividend yieldWeekly Trade Recap & Free High Return Stock Watch Alerts - newser.com
Charles River Laboratories International Inc. stock chart pattern explainedMarket Volume Report & Technical Analysis for Trade Confirmation - newser.com
Will Charles River Laboratories International Inc. stock maintain growth story2025 Technical Patterns & Weekly Return Optimization Plans - newser.com
Nicholas Company Inc. Cuts Stock Holdings in Charles River Laboratories International, Inc. $CRL - MarketBeat
How Charles River Laboratories International Inc. (RV6) stock valuation compares with sector2025 Market Outlook & High Conviction Buy Zone Alerts - newser.com
Will Charles River Laboratories International Inc. stock benefit from green energy trendsTrend Reversal & Stepwise Trade Execution Plans - newser.com
Will Charles River Laboratories International Inc. stock benefit from commodity pricesTrade Entry Summary & Fast Gain Stock Trading Tips - newser.com
Will Charles River Laboratories International Inc. (RV6) stock announce special dividendGap Down & Daily Risk Controlled Trade Plans - newser.com
Can Charles River Laboratories International Inc. stock deliver double digit returnsJuly 2025 Gainers & Safe Capital Growth Stock Tips - newser.com
Sector ETF performance correlation with Charles River Laboratories International Inc.M&A Rumor & Fast Exit Strategy with Risk Control - newser.com
Can Charles River Laboratories International Inc. (RV6) stock withstand sector downturnsForecast Cut & Stock Portfolio Risk Control - newser.com
Why hedge funds are buying Charles River Laboratories International Inc. stockMarket Activity Recap & Precise Buy Zone Tips - newser.com
Tools to monitor Charles River Laboratories International Inc. recovery probabilityQuarterly Portfolio Review & High Conviction Trade Alerts - newser.com
What earnings revisions data tells us about Charles River Laboratories International Inc.Trade Risk Summary & Technical Buy Zone Confirmations - newser.com
Applying chart zones and confluence areas to Charles River Laboratories International Inc.Market Sentiment Report & Consistent Income Trade Recommendations - newser.com
How Charles River Laboratories International Inc. stock moves on employment dataQuarterly Profit Report & Expert Approved Momentum Ideas - newser.com
Cooke & Bieler LP Increases Stock Position in Charles River Laboratories International, Inc. $CRL - MarketBeat
Sumitomo Mitsui Trust Group Inc. Acquires 2,340 Shares of Charles River Laboratories International, Inc. $CRL - MarketBeat
Bessemer Group Inc. Cuts Stock Position in Charles River Laboratories International, Inc. $CRL - MarketBeat
Charles River Laboratories (CRL): Exploring Valuation After New Drug Discovery Collaborations Boost Innovation Prospects - simplywall.st
UNIVEST FINANCIAL Corp Trims Stake in Charles River Laboratories International, Inc. $CRL - MarketBeat
How Recent Moves Are Rewriting the Story for Charles River Laboratories - Yahoo Finance
Signal strength of Charles River Laboratories International Inc. stock in tech scannersEarnings Risk Summary & Free Weekly Watchlist of Top Performers - newser.com
AlphaQuest LLC Invests $368,000 in Charles River Laboratories International, Inc. $CRL - MarketBeat
What to Expect From Charles River Laboratories' Q3 2025 Earnings Report - MSN
Why Charles River Laboratories International Inc. (RV6) stock is upgraded to buyEarnings Overview Summary & Real-Time Market Sentiment Reports - newser.com
What does recent volatility data suggest for Charles River Laboratories International Inc.July 2025 Action & High Accuracy Swing Entry Alerts - newser.com
How to integrate Charles River Laboratories International Inc. into portfolio analysis tools - newser.com
Does Charles River Laboratories International Inc. (RV6) stock trade below intrinsic valueWeekly Loss Report & Weekly Watchlist of Top Performers - newser.com
What macro factors could drive Charles River Laboratories International Inc. (RV6) stock higherEarnings Trend Report & Daily Technical Forecast Reports - newser.com
Will Charles River Laboratories International Inc. stock keep outperforming rivals2025 Market Outlook & Safe Capital Growth Tips - newser.com
What to do if you’re stuck in Charles River Laboratories International Inc.2025 Bull vs Bear & Precise Swing Trade Entry Alerts - newser.com
Using Ichimoku Cloud for Charles River Laboratories International Inc. technicalsPortfolio Risk Summary & Daily Volume Surge Signals - newser.com
Historical volatility pattern of Charles River Laboratories International Inc. visualizedSell Signal & Accurate Technical Buy Alerts - newser.com
Charles River Laboratories International, Inc. (CRL) Analyst insights, Price targets and Recommendations - Yahoo! Finance UK
Charles River Labs: Accelerating drug development as a digitally-enabled trusted partner - McKinsey & Company
Cell-based Assays Market Size to Reach USD 35.34 Billion by 2032, Driven by Demand for Drug Discovery and Advanced Biotechnology Research – SNS Insider - GlobeNewswire Inc.
Finanzdaten der Charles River Laboratories International Inc-Aktie (CRL)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.64%
1.15%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):